Investing.com2d agobearish
Citi downgrades Boston Scientific on uncertain recovery pathInvesting.com -- Citi has downgraded Boston Scientific to Neutral from Buy, citing an uncertain recovery path after a string of setbacks this year.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
63last 24h
973last 7d
109● bullish (7d)
123● bearish (7d)
212publishers
MT Newswires11d agobearish
Boston Scientific Flags Guidance Miss Amid 'Material Impact' From Cybersecurity Incident; Shares FallBoston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "mater
Quartz11d agobearish
Boston Scientific misses 2026 guidance after cyberattackThe medical device maker said it is unlikely to meet its full-year sales growth and adjusted earnings targets, and will update investors on Oct. 28
Barrons.com11d agobearish
Boston Scientific ‘Unlikely to Meet’ Earnings Guidance After Cyberattack. Stock Falls.Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.
Motley Fool23d agobearish
Stock Market Today, Aug. 26: Boston Scientific Shares Fall 5% on Cybersecurity Incident and Product RecallOn Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.
The Wall Street Journal24d agobearish
Boston Scientific Stock Drops After CyberattackShares of medical-device maker Boston Scientific are down 4.5% Wednesday on concerns that a cyber-attack against the company could hurt near-term revenue. The incident, which Boston Scientific said it detected Tuesday, caused a network outage and disruption to operations, including the ability to process and ship orders, a spokeswoman said. Evercore ISI analysts noted that a similar cyberattack against medical-device maker Stryker in March took about three weeks for the company to recover from.
Simply Wall St.51d agobearish
Boston Scientific (BSX) Is Up 7.1% After Q2 Beat, Recall And Major Restructuring Plan - Has The Bull Case Changed?Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...
The Wall Street Journal52d agobearish
Boston Scientific Cuts Outlook Ahead of RestructuringBoston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.
StockStory52d agobearish
Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses ExpectationsMedical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.
Motley Fool114d agobearish
Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth GuidanceInvestors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.